CHAPTER 01 / THE PROMISE
The breakthrough comes with a study plan.
Clair says it can already estimate hormone concentrations. Its own roadmap puts the work needed to validate those estimates in the future. Read both claims.
Read the chapter · 3 min
AN INVESTIGATION BY RYAN KERN
The Clair Health
Mirage.
01 / THE PROMISEThey sell
They sell
certainty.
The sales pitch is ahead of the science.
02 / PULL IT APARTA breakthrough pitch.
A breakthrough pitch.
A broken case.
A phase score cannot validate hormone concentrations.
Company product imagery
THE VERDICT · BY RYAN KERN
It is a mirage. Clair’s public evidence does not back the hormone-monitoring promise it sold.
THE INVESTIGATION / 06 CHAPTERS
Dismantle the pitch.
CHAPTER 02 / THE MEASUREMENT GAP
94.1% is a phase score.
The headline measures cycle-phase classification. It supplies no error for a hormone-concentration estimate. That is a rather large omission from a hormone-monitoring pitch.
Read the chapter · 3 minCHAPTER 03 / THE VALIDATION GAP
Five thousand days are not five thousand women.
The headcounts are smaller than the headlines. The prototype changed. The poster uses somebody else’s recordings. None of this establishes the performance of the bracelet for sale.
Read the chapter · 5 minCHAPTER 04 / THE CHANGING RECORD
The pitch changed. The claim did not disappear.
Hormone concentrations became “hormone-aware health.” The copy got softer. The obligation to prove the original claim did not.
Read the chapter · 3 minCHAPTER 05 / THE PRIOR TRACK RECORD
Another bracelet. Show the first breakthrough.
Clair’s CTO brought glucose-monitoring experience to a hormone-monitoring startup. The résumé sells the experience. The public record still needs to show the result.
Read the chapter · 4 minCHAPTER 06 / THE CREDIBILITY QUESTION
The names are impressive. The proof isn’t.
The affiliations, the fundraising story, the $18 million headline. I followed the credibility back to the bracelet. The names did not come with the missing results.
Read the chapter · 4 minBEHIND THE HEADLINE NUMBERS
Impressive numbers.
The wrong proof.
The percentages look convincing until you read what they actually measure.
COMPANY-REPORTED · PROTOTYPE
94.1%
Cycle-phase classification accuracy
A phase label is not a hormone concentration.
Clair’s archived FAQ reports 94.1% for assigning cycle phases using leave-one-subject-out cross-validation. That score does not tell you how wrong an estradiol reading in pg/mL could be. The decimal point cannot bridge that gap.
Publish the hormone-by-hormone errors, bias and uncertainty. Test the production bracelet.
Examine every claim →COMPANY-REPORTED · PROTOTYPE
87%
LH-surge detection sensitivity
A detected surge is not a hormone readout.
The FAQ pairs 87% sensitivity with 93% specificity and roughly one-day timing accuracy. Those numbers describe surge detection. None tells a customer the error in a continuous LH concentration reading.
Show the reference test, evaluated events, false alarms and timing errors. One flattering percentage is not the result.
Examine every claim →COMPANY-REPORTED · PROTOTYPE
40+
Participants in the archived prototype description
Days of data are not independent people.
Clair counts 127 cycles and over 5,000 days in the same account. More days from the same people do not manufacture more independent participants. The day count makes the study sound bigger; it does not make the population broader.
Test the finished bracelet in new participants across the life stages Clair markets to. Publish the results.
Examine every claim →FOLLOW THE DATA
Clair’s poster.
Somebody else’s recordings.
Clair’s poster names an external dataset and Fitbit, Dexcom and Mira equipment. The Clair bracelet is missing from its methods. That poster cannot validate hardware it does not test.
Read the poster’s methodsNEW RECEIPTS / THE FUNDRAISING DECK
The pitch they
put in the deck.
Continuous hormone readings. A clinical-validation claim. MOUs and LOIs. Clair put the promises in writing. These 13 public slides show exactly what the pitch says—and what it leaves uncheckable.
Read the deck, slide by slide ↗
FOLLOW THE WORDING
The pitch changed.
The receipts survived.
The archived pitch promised numerical hormone estimates after a future regulatory milestone. The newer headline is hormone-aware health. Changing the vocabulary does not settle the original claim.
Follow the timelineARCHIVED MATERIAL · FEBRUARY 2026
Continuous hormone monitoring
Numerical hormone estimates promised after a future regulatory milestone. A concrete claim with a concrete burden of proof.
LIVE HOMEPAGE · OCTOBER 16, 2026
“hormone-aware health”
The headline now sells wellness. The earlier promise of numerical hormone estimates still needs an answer.
THE EARLIER INVESTIGATION / OCTOBER 7, 2026
Before the hormone bracelet,
there was Argus.
Clair sells its CTO’s glucose-monitoring experience as a credential. I followed it back to Argus: another non-invasive wearable pitch, company-reported results, and a later study registered for development. The résumé is not the deliverable.
Follow the KOS connection ↗THE RECEIPTS ARE THE POINT
Don’t buy the pitch.
Open the receipts.
Read the claims. Inspect the studies. Follow the money. Clair’s own documents expose the distance between the pitch and the proof.